期刊文献+

2004年我院结核病患者出院带药分析

Analysis on Discharge Medication of Tuberculosis Inpatients in Our Hospital during 2004
下载PDF
导出
摘要 目的了解我院结核病患者的出院带药情况,为临床用药提供参考。方法利用限定日剂量方法统计2004年我院结核病患者出院带药的数量和金额,计算用药频度和日用药金额,并对有关数据进行分析。结果医疗保险患者的出院带药天数和金额少于非医疗保险患者;除一线抗结核药物之外,对氨基水杨酸异烟肼、利福喷丁、氧氟沙星和丙硫异烟胺的用药频度较高;联合用药以4联方案为主;辅助治疗以保肝药物为主。结论医疗保险制度对出院带药天数和金额有明显影响;对结核病患者出院带药应该注意耐药性和患者依从性。 OBJECTIVE: To study the discharge medication of tuberculosis inpatients of our hospital for the references of clinical medication. METHODS: The statistics on the quantity of drugs and the amount of money in discharge medication of the tuberculosis patients in our hospital in 2004 was conducted by defined daily dose method, and medication frequency and daily medication sum were computed and the associated data were analyzed as well. RESULTS: The quantity of drugs and the amount of money of the tuberculosis inpatients with medical insurance in discharge medication were less than those without. In addition to first class antituberculosis drugs, the medication frequencies of pasiniazide, rifapentine, ofloxacin and prothionamide were also high;4 agents consisted combined regimen was the chief form of drug combination;Liver protectants were the chief adjunctive therapy. CONCLUSIONS: Medical insurance policy has significant effect on during of administration and consumption sum in discharge medication. Attention should be paid to drug resistance and dependence in the discharge medication of tuberculosis patients.
出处 《中国药房》 CAS CSCD 北大核心 2006年第5期357-359,共3页 China Pharmacy
关键词 抗结核药物 限定日剂量 用药频度 日用药金额 医疗保险 分析 Antituberculosis drugs Defined Daily Dose Medication frequency Daily medication volume Medical insurance Analysis
  • 相关文献

参考文献4

二级参考文献13

  • 1K.TOMAN 阚冠卿.结核病病例发现和化学治疗问答[M].北京:中国科学技术出版社,1992.83,85,87,89.
  • 2Brien RJ,Vernon AA.New tuberculosis drug development how can we do better[J] .Am J Respir Crit Care Med, 1998,157(6): 1 705.
  • 3Josefson D.FDA appoves tuberculosis drug(New)[J].BMJ, 1998,317: 11.
  • 4McGregor MM,Olliaro P,Wolmarans L,et al.Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis[J] .Am J Respir Crit Care Med, 1996,154(5): 1 462.
  • 5Tam CM,Chan SL,Lam CW,et al.Rifapentine and lsoniazid in the continuation phase of treating pulmonary tuberculosis[J] .Am J Respir Crit Care Med, 1998, 157(6): 1 726.
  • 6Deol P,Khuller GK,Joshi K.Therapentio efficacies of isoniazid and rifampin encapsulated in lung- specific stealth liposomes against mycoba cterium tuberculosis infection induced in mice [J] . Antimicrob Agents Chemother, 1997,41(6) :1 211.
  • 7ATC INDEX with DDDs 2000. WHO Collaborating Center for Drug Statistics Methodology : 2000. 1.
  • 8Cuidelines for ATC Classification and DDD Assignment. WHO Collaborating Center for Drug Statistics Methodology,. 1998. 1, 20- 6.
  • 9European drug utilization research group. Euro drug bulletin No. 1 April 1997.European Journal of Clinical Pharmacology. 52 - 3. May 1997.
  • 10Action programme on essential drug. 3 May 1999U RL: wwww. who, org/dap/edmconf, htm

共引文献84

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部